跳至主要内容
临床试验/NCT00600093
NCT00600093终止2 期

Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine

Rabin Medical Center1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
20
试验地点
1
主要终点
Mortality, Surgical site infection, Pneumonia, Myocardial Infarction, Cerebral Vascular Accident (CVA).

研究概览

简要总结

The purpose of this study is to determine whether administrating of Amantadine (a dopamine agonist) to patients suffering from Parkinson disease during the perioperative period is safe, and to asses potential benefits of this treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient with a diagnosis of Parkinson Disease refered for surgery at our institution.

排除标准

  • Cardiac and neurosurgical procedures
  • Inability to sign informed Consent
  • allergy to Amantadine
  • Congestive heart failure
  • Arrythmia (including bradycardia below 55 bpm)
  • renal failure (creatinin above 1.5)
  • If a patient will develop agitation or delirium lasting longer then 8 hours he will not receive the second dose of amantadine.

研究组 & 干预措施

A

Experimental

干预措施: Amantadine (Drug)

结局指标

主要结局

Mortality, Surgical site infection, Pneumonia, Myocardial Infarction, Cerebral Vascular Accident (CVA).

时间窗: 28 days

次要结局

  • UPDRS score(2,28 days)
  • Pain (vas score), Analgetic drugs requirement(2 days)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验